Exelixis, Inc. (EXEL)
58.39
+0.45
(+0.78%)
USD |
NASDAQ |
Oct 02, 16:00
58.37
-0.02
(-0.03%)
After-Hours: 20:00
Exelixis Price : 58.39 for Oct. 2, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 02, 2026 | 58.11 | 58.97 | 57.94 | 58.39 | 1.969M |
| Oct 01, 2026 | 58.54 | 59.28 | 57.76 | 57.94 | 1.369M |
| Sep 30, 2026 | 58.90 | 61.14 | 58.40 | 58.41 | 3.065M |
| Sep 29, 2026 | 58.06 | 59.12 | 57.53 | 58.65 | 2.244M |
| Sep 28, 2026 | 57.97 | 58.66 | 57.51 | 58.37 | 1.279M |
| Sep 25, 2026 | 58.25 | 58.62 | 57.63 | 58.16 | 1.990M |
| Sep 24, 2026 | 56.70 | 57.99 | 56.58 | 57.95 | 1.926M |
| Sep 23, 2026 | 58.22 | 58.66 | 56.26 | 56.73 | 1.432M |
| Sep 22, 2026 | 57.65 | 59.09 | 57.33 | 58.15 | 1.860M |
| Sep 21, 2026 | 58.61 | 58.80 | 56.90 | 57.22 | 2.103M |
| Sep 18, 2026 | 58.28 | 59.15 | 57.90 | 58.36 | 5.243M |
| Sep 17, 2026 | 57.23 | 58.52 | 57.23 | 58.49 | 1.786M |
| Sep 16, 2026 | 57.04 | 57.78 | 56.32 | 56.78 | 1.880M |
| Sep 15, 2026 | 55.93 | 56.97 | 54.94 | 56.90 | 1.980M |
| Sep 14, 2026 | 56.44 | 57.07 | 55.91 | 56.21 | 1.739M |
| Sep 11, 2026 | 56.76 | 57.43 | 54.54 | 56.12 | 2.917M |
| Sep 10, 2026 | 58.33 | 58.33 | 57.23 | 57.43 | 1.790M |
| Sep 09, 2026 | 57.60 | 58.36 | 56.95 | 58.33 | 1.770M |
| Sep 08, 2026 | 58.97 | 59.41 | 57.55 | 57.67 | 2.539M |
| Sep 04, 2026 | 58.50 | 59.26 | 58.46 | 59.01 | 1.581M |
| Sep 03, 2026 | 58.75 | 59.72 | 58.20 | 59.13 | 2.142M |
| Sep 02, 2026 | 57.21 | 59.11 | 56.70 | 58.53 | 2.851M |
| Sep 01, 2026 | 54.75 | 56.97 | 54.75 | 56.89 | 2.414M |
| Aug 31, 2026 | 54.10 | 55.02 | 53.43 | 54.64 | 2.246M |
| Aug 28, 2026 | 55.14 | 55.25 | 54.12 | 54.45 | 1.487M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Alnylam Pharmaceuticals, Inc. | 219.72 |
| BioMarin Pharmaceutical, Inc. | 57.18 |
| Cytokinetics, Inc. | 65.60 |
| Emergent BioSolutions, Inc. | 6.33 |
| Gilead Sciences, Inc. | 144.74 |
Price Related Metrics
| PE Ratio | 18.34 |
| PS Ratio | 6.483 |
| PEG Ratio | 0.348 |
| Price to Book Value | 7.882 |
| Price to Free Cash Flow | 13.47 |
| Earnings Yield | 5.45% |
| Market Cap | 14.53B |
| PEGY Ratio | 0.348 |
| Operating PE Ratio | 15.92 |
| Normalized PE Ratio | 18.05 |